Oral tolerance is classic method by which one can induced immunologic tolerance and it is now recognized to be an active immunologic process mediated by multiple mechanisms including active suppression, anergy, and deletion. Low doses of oral antigen administration favor induction of regulatory T cells whereas higher doses induce anergy or deletion. Over the past decade there has been increasing interest in oral (and mucosal) tolerance with the demonstration that orally administered antigen can suppress several animal models of autoimmune disease includingEAE. Furthermore mucosal antigen administration may have even broader biologic implications as a therapeutic modality for neurologic diseases including Alzheimer's disease and stroke. Human trials of oral tolerance have given mixed results and a great deal remains to be learned about the basic mechanisms that underlie immune responses in the gut associated lymphoid tissues (GALT) and both the inductive and effector mechanisms associated with oral tolerance. We will continue our investigation of oral tolerance as one of the projects in the program project grant and will address the following questions: 1. What is the role of T-bet transcription factor in the induction of mucosal tolerance? T-bet is a major regulator of Thl differentiation and we have found that T bet -/- animals have a phenotype analogous to that observed in low dose oral tolerance. We will investigate the role of T-bet in the induction of the different mechanisms of oral tolerance. 2. What is the role of T-bet and TIM molecules in TGF-0 producing Th3 type regulatory cells? We have shown that the gut is a unique environment that leads to the induction of TGF-p (Th3 type) secreting regulatory cells and cells which express LAP on their surface. We will investigate T-bet and TIM molecules in Th3 clones derived from the mesenteric lymph nodes of low dose orally tolerized animals. In addition, we have generated a TGF-P transgenic mouse in which the production of TGF-|3 is inducible in T cells, driven by the IL-2 promoter. These mice will be used to investigate the effector function of TGF-P secreting regulatory cells. 3. What are the mechanisms associated with enhancement of oral tolerance to glatiramer acetate and MOG by novel mucosal adjuvants that polarize towards Thl vs. Th2 responses . Mucosally active adjuvants may be crucial for the induction of immune responses of significant strength to be effective as immune therapy. We will investigate unique adjuvants that polarize towards Thl/Th2-Th3 responses when given orally in the investigation of glatiramer acetate, a immunomodulatory drug currently approved for the treatment of MS, and MOG an encephalitogenic myelin antigen.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Program Projects (P01)
Project #
5P01NS038037-08
Application #
7684175
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Project Start
Project End
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
8
Fiscal Year
2008
Total Cost
$314,697
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Kitz, Alexandra; de Marcken, Marine; Gautron, Anne-Sophie et al. (2016) AKT isoforms modulate Th1-like Treg generation and function in human autoimmune disease. EMBO Rep 17:1169-83
Murugaiyan, Gopal; da Cunha, Andre Pires; Ajay, Amrendra K et al. (2015) MicroRNA-21 promotes Th17 differentiation and mediates experimental autoimmune encephalomyelitis. J Clin Invest 125:1069-80
Zhu, Chen; Sakuishi, Kaori; Xiao, Sheng et al. (2015) An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction. Nat Commun 6:6072
Van Haren, Keith; Tomooka, Beren H; Kidd, Brian A et al. (2013) Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis. Mult Scler 19:1726-33
Wu, Chuan; Pot, Caroline; Apetoh, Lionel et al. (2013) Metallothioneins negatively regulate IL-27-induced type 1 regulatory T-cell differentiation. Proc Natl Acad Sci U S A 110:7802-7
Rangachari, Manu; Kuchroo, Vijay K (2013) Using EAE to better understand principles of immune function and autoimmune pathology. J Autoimmun 45:31-9
Xiao, Sheng; Brooks, Craig R; Zhu, Chen et al. (2012) Defect in regulatory B-cell function and development of systemic autoimmunity in T-cell Ig mucin 1 (Tim-1) mucin domain-mutant mice. Proc Natl Acad Sci U S A 109:12105-10
Murugaiyan, Gopal; Beynon, Vanessa; Pires Da Cunha, Andre et al. (2012) IFN-? limits Th9-mediated autoimmune inflammation through dendritic cell modulation of IL-27. J Immunol 189:5277-83
Liu, Sue M; Sutherland, Andrew P R; Zhang, Zheng et al. (2012) Overexpression of the Ctla-4 isoform lacking exons 2 and 3 causes autoimmunity. J Immunol 188:155-62
Lozano, Ester; Dominguez-Villar, Margarita; Kuchroo, Vijay et al. (2012) The TIGIT/CD226 axis regulates human T cell function. J Immunol 188:3869-75

Showing the most recent 10 out of 128 publications